About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

ML Decision Model for G-NEC Adjuvant Therapy | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDNCT06663852

ML Decision Model for G-NEC Adjuvant Therapy

Gastric neuroendocrine carcinoma (G-NEC) is a rare and aggressive tumor originating from neuroendocrine cells in the stomach lining. It is characterized by a high propensity for recurrence and a gener...

Lead sponsor: Chang-Ming Huang, Prof.•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Chang-Ming Huang, Prof.

Age

All ages

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•(1) patients who underwent radical surgery without any neoadjuvant therapy;
•(2) pathology confirmed NEC or mixed adenoneuroendocrine carcinoma (MANEC).

Exclusion Criteria

•(1) history of other malignant neoplasms;
•(2) treatment with endoscopic submucosal dissection or endoscopic mucosal resection or thoracotomy;
•(3) incomplete clinical data (including pathological, adjuvant chemotherapy, and follow-up information);
•(4) receipt of alternative adjuvant treatment regimens;
•(5) death within 30 days postoperatively.

Related studies

RECRUITINGPhase 2

PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer

NCT05311566 · Cervical Carcinoma, Chemoradiotherapy, and more

Active Not Recruiting

Response Times in Danish Emergency Medical Services

NCT06666647 · Emergency Medical Services, Response, and more

Niraparib Plus Anlotinib for Recurrent Ovarian Cancer

NCT05311579 · Ovarian Carcinoma, Survival Outcomes, and more

Chromosomal Instability in Ovarian Cancer

NCT05310357 · Epithelial Ovarian Cancer, High-grade Serous Ovarian Carcinoma, and more

Overall Survival of Large Cell Neuroendocrine Lung Cancer Patients - a Retrospective Study

NCT03998332 · Survival Outcomes of Patients With Pulmonary LCNEC

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: November 27, 2024Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment1,505

Start dateJan 2024

Last updatedNov 27, 2024

Condition

Gastric Neuroendocrine Carcinoma (G-NEC)Postoperative Adjuvant Therapy for G-NEC Survival Outcomes Machine Learning

Locations shown

Fujian Medical University

Fuzhou, Fujian

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 27, 2024Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions